会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 22. 发明授权
    • Enzyme catalysis in carbon dioxide fluids
    • 二氧化碳液体中的酶催化
    • US06211422B1
    • 2001-04-03
    • US09352249
    • 1999-07-13
    • Joseph M. DeSimoneRuben G. CarbonellStephanie A. CretteJonathan L. Kendall
    • Joseph M. DeSimoneRuben G. CarbonellStephanie A. CretteJonathan L. Kendall
    • C12P100
    • C12P41/001C12P1/00Y02P20/544
    • A method for the enzymatic production of a desired product in a liquid or supercritical carbon dioxide fluid. The method comprises: (a) providing a reaction mixture comprising at least one reaction substrate and a crosslinked enzyme crystal catalyst in a liquid or supercritical carbon dioxide fluid; and (b) reacting said substrate with said crosslinked enzyme crystal catalyst in said carbon dioxide fluid to produce said product. The reacting step is typically followed by the step of (c) separating the product from said reaction mixture. The crosslinked enzyme crystal catalyst preferably comprises an enzyme crystal crosslinked with a multifunctional crosslinking agent, said crosslinked enzyme crystal having resistance to exogeneous proteolysis, such that the crosslinked enzyme crystal retains at least about 80 percent of its initial activity after incubation for three hours in the presence of a concentration of Pronase™ protease that causes the soluble uncrosslinked form of the enzyme that is crystallized to form said enzyme crystal that is crosslinked to lose at least about 80 percent of its initial activity under the same conditions. Reaction mixtures useful for carrying out the foregoing method and product mixtures produced by the foregoing method are also disclosed.
    • 在液体或超临界二氧化碳流体中酶促生产所需产物的方法。 该方法包括:(a)在液体或超临界二氧化碳流体中提供包含至少一个反应底物和交联的酶晶体催化剂的反应混合物; 和(b)使所述底物与所述交联的酶晶体催化剂在所述二氧化碳流体中反应以产生所述产物。 反应步骤通常是(c)从所述反应混合物中分离产物的步骤。 交联酶晶体催化剂优选包含与多官能交联剂交联的酶晶体,所述交联酶晶体具有对外源性蛋白水解的抗性,使得交联的酶晶体在孵育3小时后保留其初始活性的至少约80% 存在一种浓度的Pronase TM蛋白酶,其引起可溶性的未交联形式的酶,其被结晶以形成所述交联的酶晶体,以在相同条件下损失其初始活性的至少约80%。 还公开了可用于实施上述方法的反应混合物和通过前述方法制备的产物混合物。
    • 24. 发明授权
    • Alpha-1 proteinase inhibitor binding peptides
    • α-1蛋白酶抑制剂结合肽
    • US5985836A
    • 1999-11-16
    • US127574
    • 1998-07-31
    • Patrick D. BastekJohn M. LangGeorge A. BaumbachRuben G. Carbonell
    • Patrick D. BastekJohn M. LangGeorge A. BaumbachRuben G. Carbonell
    • C07K7/06A61K38/00A61K38/02C07K5/00C07K7/00
    • C07K7/06
    • Peptides which bind to alpha-1 Proteinase inhibitor (AlPI) are disclosed. The peptides have an available AlPI binding domain which may be any of the following preferred sequences: Val Ile Trp Leu Val Arg, Ile Ile Trp Leu Tyr Lys, Arg Tyr Arg Ile Phe Ile, Arg Ala Phe Trp Tyr Ile, Arg Phe Ile Tyr Tyr Thr, Tyr Lys Phe Arg Phe Trp, Leu Ile Val His Arg Trp, Pro Tyr Trp Ile Val Arg, Ala Arg Trp Tyr Ile His, Gln Tyr His Phe Trp Tyr, Arg Leu Trp Arg Tyr Gly, Val Ile Tyr Leu Val Arg, Val Ile Phe Leu Val Arg, Lys Ile Phe Leu Val Arg, Arg Ile Phe Leu Val Arg, His Ile Phe Leu Val Arg, Arg Val Leu Phe Ile Val, or Arg Val Leu Phe Ile His (SEQ ID NOS: 1-8, 10, 11, 15, 36, 37, 45, 46, 47, 61, and 62 respectively). A method of using peptides having these available binding domains in an affinity chromatography process to purify AlPI is described.
    • 公开了结合α-1蛋白酶抑制剂(AlPI)的肽。 肽具有可用的AlPI结合结构域,其可以是以下优选的序列:Val Ile Trp Leu Val Arg,Ile Ile Trp Leu Tyr Lys,Arg Tyr Arg Ile Phe Ile,Arg Ala Phe Trp Tyr Ile,Arg Phe Ile Tyr Tyr Thr,Tyr Lys Phe Arg Phe Trp,Leu Ile Val His Arg Trp,Pro Tyr Trp Ile Val Arg,Ala Arg Trp Tyr Ile His,Gln Tyr His Phe Trp Tyr,Arg Leu Trp Arg Tyr Gly,Val Ile Tyr Leu Val Arg,Val Ile Phe Leu Val Arg,Lys Ile Phe Leu Val Arg,Arg Ile Phe Leu Val Arg,His Ile Phe Leu Val Arg,Arg Val Leu Phe Ile Val或Arg Val Leu Phe Ile His(SEQ ID NOS:1 分别为-8,10,11,15,36,37,45,46,47,61和62)。 描述了在亲和层析方法中使用具有这些可用结合域的肽纯化AlPI的方法。